Latest Capital Raises News

DXN Limited reported a robust 58.1% revenue increase to $4.8 million in Q2 FY25, underpinned by strategic capital raising and new product innovation targeting AI infrastructure. The company is advancing key mining and telecom projects while streamlining operations to support its ambitious $16 million revenue guidance for FY25.

Paradigm Biopharmaceuticals has secured FDA clearance for its phase 3 knee osteoarthritis trial and raised $16 million to fund its next clinical steps, positioning the company for a pivotal year ahead.

NSX Limited reports a $1.6 million cash injection from ISXFEU, completes the ClearPay joint venture sale, and reduces operational costs in its 2Q25 activities report, while facing delays in share issuance approval.

BlinkLab has launched its pivotal FDA registrational study for its AI-driven autism diagnostic app, BlinkLab Dx 1, following positive FDA feedback and promising preliminary results.

Icon Energy Limited reported a $455K cash balance and issued 100 million shares this quarter to sustain operations amid ongoing uncertainty over the ATP 855 permit renewal.

Impact Minerals Limited reported its December 2024 quarterly cash flow, revealing ongoing exploration expenditures and a significant $2.87 million grant to commercialise its High Purity Alumina process at Lake Hope.

NH3 Clean Energy has made significant strides in its WAH2 Project, finalising critical commercial agreements and progressing technical work ahead of Front End Engineering and Design (FEED) entry scheduled for Q1 2025. The company also completed a capital raise to support these developments.

Bluechiip Limited reported a $221,000 net cash outflow for Q2 FY2025, with cash reserves dwindling to $121,000. The company has initiated a strategic review and plans a capital raise to secure its future.

Enova Mining has completed a significant drilling campaign at its CODA North project, confirming high-grade rare earth element mineralisation, while securing $1.5 million in new funding to accelerate exploration and metallurgical testing.

Zelira Therapeutics has secured a fourth funding tranche of US$681,000, advancing its HOPE® Autism Spectrum Disorder FDA trial process and bringing total funding to US$3.25 million. The company is progressing clinical validation and product development, including the transformation of Zenivol® into a capsule formulation.

Midas Minerals reports steady progress in its Western Australian gold and base metals projects alongside a $1.6 million capital raising, positioning the company for upcoming drill target definitions.

Traka Resources reports steady progress in its December 2024 quarter, focusing on exploration at Gorge Creek and Cranbrook while withdrawing from Mozambique projects to sharpen its strategic focus.